Stock listing
Frankfurt:1YR Immunovia AB Aktie
German listing (Frankfurt) of Immunovia AB · home listing Stockholm:IMMNOV
Follow Immunovia AB into a list and get an email when it puts out news.
Share price · FWB:1YR
€0.0001 EUR -0.0013 (-92.9%)
Close on Oct 30, 2026
- Day range
- €0.0001 – €0.0001 EUROct 30, 2026
- Market cap
- €67,267 EURAt the close on Oct 30, 2026 · price × 672.7M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:IMMNOV · Home | 0.052 SEK | +0.001 (+2.8%) | 9,905,975 | 0.055 | 0.061 | 0.051 | 0.050 | Close on Nov 2, 2026 |
| LSE:0G8X | 0.071 SEK | -0.016 (-18.4%) | 500,000 | 0.071 | 0.071 | 0.071 | 0.087 | Close on Oct 27, 2026 |
| Frankfurt:1YR | €0.0001 EUR | -0.0013 (-92.9%) | — | €0.0001 | €0.0001 | €0.0001 | €0.0014 | Close on Oct 30, 2026 |
- Ticker
- Frankfurt:1YR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 28, 2026
Immunovia announces final terms of rights issue
Latest earnings call · Aug 6, 2026
Immunovia (Stockholm:IMMNOV) Q2 2026 Earnings Call
Replay and transcript
Latest deck · May 7, 2026
Q1 2026 Earnings Presentation
Earnings · 30 slides
Calls
Replays
Immunovia (Stockholm:IMMNOV) Q2 2026 Earnings Call
Thu, Aug 06, 2026 · 9:00 AM ET
Watch TranscriptImmunovia (Stockholm:IMMNOV) Q1 2026 Earnings Call
Thu, May 07, 2026 · 9:00 AM ET
Watch TranscriptImmunovia (Stockholm:IMMNOV) Q4 2025 Earnings Call
Tue, Feb 24, 2026 · 9:00 AM ET
Watch Transcript
Latest news
Financings
Rights offering of units consisting of shares and warrants of series TO 4
Oct 28, 2026 · US$6.38M
Update: about SEK 63.4M · SEK 0.06 a unit · 1 warrant at SEK 0.03 · APREA Partners AB +2
Dealers: APREA Partners AB (co-lead), Carlsquare AB (co-lead), Vator
Buyers: Jeff Borcherding (committed to subscribe for at least his pro rata share)
Insiders: Several board members and management, including CEO Jeff Borcherding, gave subscription undertakings totalling approximately SEK 1 million
Use of proceeds: US commercialization of PancreaSure incl. sales and marketing, clinical studies to support reimbursement, and working capital
Decks
Q1 2026 Earnings Presentation
Earnings · 30 slides · May 7, 2026
Q4 2025 Earnings Presentation
Earnings · 17 slides · Feb 24, 2026
Q2 2025 Earnings Presentation
Earnings · 21 slides · Aug 28, 2025
Q1 2025 Earnings Presentation
Earnings · 20 slides · May 14, 2025
Immunovia AB on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 18 in the last 12 months · 18 in all · newest Oct 28, 2026 · oldest 2026
- Calls
- 9 calls with a replay · 9 with a transcript · latest Aug 6, 2026
- Decks
- 13 decks · latest May 7, 2026
Where Immunovia AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:IMMNOV · Home listing | Stockholm | Sweden | SEK |
| gettex:1YR | gettex | Germany | EUR |
| LSE:0G8X | LSE | United Kingdom | SEK |
| Aquis:IMMNOS | Aquis | United Kingdom | SEK |
| Aquis:IMMNOS | Aquis | United Kingdom | SEK |
| Frankfurt:1YR · This page | Frankfurt | Germany | EUR |
| Munich:1YR | Munich | Germany | EUR |
| OTC:IMMVF | OTC | United States | USD |
Log in to ask 6ix AI your own questions about Immunovia AB.